Veeva Systems (VEEV) AI Stock Analysis

• Market Cap: $46.13B
• Dividend Yield: N/A
• Average Volume (3M): 1.41M
• Price to Earnings (P/E): 59.2
• Beta (1Y): 1.07
• Revenue Growth: 14.78%
• EPS Growth: 39.33%
• Country: US
• Employees: 7,291
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.97
• Shares Outstanding: 163,412,280
• 10 Day Avg. Volume: 1,117,027
• 30 Day Avg. Volume: 1,410,395
• PEG Ratio: 6.45
• Price to Book (P/B): 7.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 38.08
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 4.04
• Enterprise Value/Gross Profit: 20.30
• Enterprise Value/Ebitda: 15.61
• 1Y Price Target: $295.52
• Price Target Upside: 4.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 23

• Rating: 81 Outperform
• Price Target: $323.00 ▲(14.35%Upside)

Veeva Systems scores highly due to its robust financial performance and positive earnings call, highlighting strong revenue growth and strategic advancements in AI and CRM markets. However, the high P/E ratio and potential overbought technical indicators present valuation concerns and a risk of short-term pullbacks.

Positive Factors

Product Development

Crossix has an active product pipeline with compelling feature releases planned, which may persist demand tailwinds.

Strategic Positioning

Crossix is increasingly embedded in multi-brand master services agreements, enhancing Veeva's strengths in retention and upselling opportunities.

Negative Factors

Competitive Challenges

Veeva Systems has faced recent losses in top 20 CRM deals, with competitors like Salesforce offering highly customized solutions.

Regulatory Risks

Regulatory risks exist but are expected to lead to newer disclosure and compliance requirements rather than outright bans, which might lead to a reallocation of omni-channel budgets.

Veeva Systems Business Overview & Revenue Model

Company Description

Veeva Systems Inc. is a leading provider of cloud-based software solutions specifically designed for the global life sciences industry. The company offers a comprehensive suite of applications that enable pharmaceutical and biotechnology companies to reduce costs, increase productivity, and improve compliance throughout the product lifecycle. Veeva's core products include Veeva Vault, a content management and collaboration solution, Veeva CRM, a customer relationship management platform tailored for life sciences, and Veeva Network, a master data management application.

How the Company Makes Money

Veeva Systems generates revenue primarily through subscription fees for its cloud-based software solutions offered to the life sciences sector. The company's revenue model is largely based on multi-year contracts with customers, which provide a steady and predictable income stream. Key revenue streams include Veeva Vault, Veeva CRM, and Veeva Network, each catering to different aspects of the life sciences industry such as content management, customer engagement, and data management, respectively. Additionally, Veeva offers professional services, including implementation, training, and support, which contribute to its overall earnings. Strategic partnerships with major pharmaceutical companies and other stakeholders in the life sciences ecosystem further enhance Veeva's revenue potential by expanding its market reach and customer base.

Veeva Systems Financial Statement Overview

Summary

Veeva Systems exhibits strong financial performance with robust revenue growth, excellent profitability margins, and a stable balance sheet with minimal leverage. The company's cash flow management is exceptional, supporting operational and growth needs effectively. Potential risks include a slight decrease in EBIT Margin and the need to maintain growth momentum.

Income Statement

Veeva Systems demonstrates strong revenue growth with a Revenue Growth Rate of 17.5% from the previous year and a solid Gross Profit Margin of 75.5% for TTM. The company maintains a high EBIT Margin of 27% and a Net Profit Margin of 27.3%, indicating robust profitability. However, there is a slight decrease in EBIT Margin compared to the previous year, which could be a point of concern if it continues.

Balance Sheet

The balance sheet is highly stable with a low Debt-to-Equity Ratio of 0.0124, showcasing minimal leverage and financial risk. The Equity Ratio stands at 80%, reflecting a strong capital base. The Return on Equity (ROE) is impressive at 12.6% for TTM, indicating efficient use of equity capital to generate profits. The strong liquidity position further enhances the company's financial stability.

Cash Flow

Veeva Systems exhibits consistent cash flow generation with a strong Operating Cash Flow to Net Income Ratio of 1.54 and a Free Cash Flow to Net Income Ratio of 1.54, highlighting efficient cash conversion. The Free Cash Flow Growth Rate is 10.4%, demonstrating healthy cash flow management. The company's cash flow performance supports its operational and growth needs effectively.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.75B	2.36B	2.16B	1.85B	1.47B
Gross Profit	2.05B	1.69B	1.55B	1.35B	1.06B
EBITDA	730.82M	461.96M	488.21M	532.94M	407.25M
Net Income	714.14M	525.71M	487.71M	427.39M	380.00M
Balance Sheet
Total Assets	7.34B	5.91B	4.80B	3.82B	3.05B
Cash, Cash Equivalents and Short-Term Investments	5.15B	4.03B	3.10B	2.38B	1.66B
Total Debt	75.78M	55.77M	60.98M	54.59M	63.12M
Total Liabilities	1.51B	1.27B	1.09B	904.83M	779.75M
Stockholders Equity	5.83B	4.64B	3.72B	2.91B	2.27B
Cash Flow
Free Cash Flow	1.09B	885.14M	777.98M	761.97M	551.81M
Operating Cash Flow	1.09B	911.34M	780.47M	764.46M	551.25M
Investing Cash Flow	-700.14M	-1.08B	-1.01B	-346.15M	-333.63M
Financing Cash Flow	26.11M	-16.19M	-19.38M	-4.14M	33.82M

Veeva Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 282.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VEEV, the sentiment is Positive. The current price of 282.47 is above the 20-day moving average (MA) of 281.74, above the 50-day MA of 267.39, and above the 200-day MA of 234.45, indicating a bullish trend. The MACD of 3.08 indicates Positive momentum. The RSI at 55.43 is Neutral, neither overbought nor oversold. The STOCH value of 61.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VEEV.

Veeva Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VEEV	81 Outperform	$46.13B	59.19	14.07%	―	14.78%	39.33%
DOCS	73 Outperform	$11.65B	56.36	22.50%	―	19.98%	53.10%
GEHC	73 Outperform	$34.09B	15.65	26.32%	0.19%	1.55%	38.51%
HQY	66 Neutral	$8.42B	70.01	5.77%	―	19.21%	50.06%
BTSG	63 Neutral	$3.57B	71.29	2.30%	―	23.40%	―
Sector *	60 Neutral	HK$16.12B	5.55	-7.44%	3.87%	11.55%	-28.15%
TEM	43 Neutral	$9.68B	―	-1252.79%	―	42.93%	-160.27%

Veeva Systems Corporate Events

Veeva Systems Holds Annual Shareholder Meeting

On June 18, 2025, Veeva Systems held its Annual Meeting where shareholders voted on two key proposals. The first proposal involved the election of directors to serve until the 2026 annual meeting, with all nominees successfully elected. The second proposal ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending January 31, 2026.

The most recent analyst rating on (VEEV) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Veeva Systems stock, see the VEEV Stock Forecast page.